Apixaban + Standard of care
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Symptomatic Aortic Stenosis
Conditions
Symptomatic Aortic Stenosis, Eligible for Transcatheter Aortic Valve Replacement
Trial Timeline
Aug 26, 2016 → Oct 15, 2020
NCT ID
NCT02664649About Apixaban + Standard of care
Apixaban + Standard of care is a phase 3 stage product being developed by Pfizer for Symptomatic Aortic Stenosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02664649. Target conditions include Symptomatic Aortic Stenosis, Eligible for Transcatheter Aortic Valve Replacement.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02664649 | Phase 3 | Completed |
| NCT02464969 | Approved | Completed |
Competing Products
20 competing products in Symptomatic Aortic Stenosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sodium hyaluronate + placebo injection | Daiichi Sankyo | Phase 3 | 77 |
| ISV-305 | Sun Pharmaceutical | Phase 3 | 77 |
| rabeprazole sodium + Placebo | Eisai | Phase 3 | 77 |
| Verinurad + Febuxostat + Dapagliflozin | AstraZeneca | Phase 2 | 52 |
| RDEA3170 + Febuxostat + Benzbromarone | AstraZeneca | Phase 1/2 | 41 |
| Esomeprazole + Matching placebo | AstraZeneca | Phase 3 | 77 |
| DFV890 + Placebo | Novartis | Phase 2 | 52 |
| Omalizumab + Omalizumab + Placebo | Novartis | Phase 2 | 52 |
| Pasireotide + Octreotide | Novartis | Phase 3 | 77 |
| Tegaserod | Novartis | Phase 2 | 52 |
| valsartan | Novartis | Approved | 85 |
| Atorvastatin - Cholestyramine - Sitosterol | Pfizer | Pre-clinical | 22 |
| Epoetin biosimilar | Pfizer | Pre-clinical | 22 |
| Azithromycin plus chloroquine | Pfizer | Phase 3 | 76 |
| Mavacamten | Bristol Myers Squibb | Approved | 84 |
| Aficamten + Placebo | Sanofi | Phase 3 | 76 |
| Vandetanib 300 mg | Sanofi | Pre-clinical | 22 |
| REGN7508 + Acetylsalicylic Acid (ASA) + Placebo | Regeneron Pharmaceuticals | Phase 3 | 76 |
| Rivaroxaban + Placebo | Bayer | Phase 3 | 74 |
| Droxidopa capsules + Placebo capsules | Lundbeck | Approved | 82 |